Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

Pancreatic endocrine tumors are rare diseases and devising a clinically effective prognostic stratification of patients is a major clinical challenge. This study aimed at assessing whether the tumor-node-metastasis (TNM)-based staging and proliferative activity-based grading recently proposed by the European NeuroEndocrine Tumors Society (ENETS) have clinical value. TNM was applied to 274 patients with histologically diagnosed pancreatic endocrine tumors operated from 1991 to 2005, with last follow-up at December 2007. According to World Health Organization (WHO) classification, 246 were well-differentiated neoplasms (51 benign, 56 uncertain behavior, 139 carcinomas) and 28 poorly differentiated carcinomas. Grading was based on Ki67 immunohistochemistry. Survival analysis not only ascertained the prognostic value of the TNM system but also highlighted that in the absence of nodal and distant metastasis, infiltration and tumor dimensions over 4 cm had prognostic significance. T parameters were then appropriately modified to reflect this weakness. The 5-year survival for modified TNM stages I, II, III and IV were 100, 93, 65 and 35%, respectively. Multivariate analysis identified TNM stages as independent predictors of death, in which stages II, III and IV showed a risk of death of 7, 29 and 58 times higher than stage I tumors (P<0.0001). Ki67-based grading resulted an independent predictor of survival with cut-offs at 5 and 20%. In conclusion, WHO classification assigns clinically significant diagnostic categories to pancreatic endocrine tumors that need prognostic stratification by applying a staging system. The ENETS–TNM provides the best option, but it requires some modifications to be fully functional. The modified TNM described in this study ameliorates the clinical applicability and prediction of outcome of the ENETS–TNM; it (i) assigns a risk of death proportional to the stage at the time of diagnosis, and (ii) allows a clinically based staging of patients, as the T parameters as modified permit their clinical-radiological recognition. Ki67-based grading discerns prognosis of patients with same stage diseases.

[1]  H. Friess,et al.  Clinical outcome and long‐term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas , 2008, The British journal of surgery.

[2]  C. Ko,et al.  Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. , 2007, Journal of the American College of Surgeons.

[3]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[4]  C. Doglioni,et al.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. , 2009, Human pathology.

[5]  B. Eriksson,et al.  Endocrine tumours of the pancreas. , 2005, Best practice & research. Clinical gastroenterology.

[6]  T. de Baère,et al.  Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. , 2001, European journal of cancer.

[7]  G. Tamburrano,et al.  Pancreatic endocrine tumours. , 1999, Italian journal of gastroenterology and hepatology.

[8]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[9]  P. Bejarano WHO 2004 Criteria and CK19 are Reliable Prognostic Markers in Pancreatic Endocrine Tumors , 2009 .

[10]  B. Weinhold Epigenetics: The Science of Change , 2006, Virchows Archiv.

[11]  L. Kvols,et al.  Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma , 2007, Neuroendocrinology.

[12]  G. Klöppel,et al.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors , 2007, Virchows Archiv.

[13]  G. Klöppel,et al.  Tumors of the Pancreas , 1997 .

[14]  M. Falconi,et al.  Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma , 2007, Neuroendocrinology.

[15]  R. Jensen,et al.  Gastrinoma (Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[16]  A. Scarpa,et al.  Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. , 2006, Endocrine-related cancer.

[17]  Heinz Höfler,et al.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut , 2004, Virchows Archiv.

[18]  A. Scarpa,et al.  Endocrine neoplasms of the pancreas: pathologic and genetic features. , 2009, Archives of pathology & laboratory medicine.

[19]  S. Willich,et al.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.

[20]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[21]  I. Francis,et al.  Endocrine Neoplasms , 1997, Cancer Treatment and Research.

[22]  M. Falconi,et al.  Rare Functioning Pancreatic Endocrine Tumors , 2006, Neuroendocrinology.